Daniel A. Ermann
( out of 35 reviews )

Daniel A. Ermann, MD

Languages spoken: English

TO MAKE AN APPOINTMENT CALL:

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-0236

  • Dr. Daniel Ermann joined the Division of Hematology/Hematologic malignancies in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. He specializes in the treatment of patients with chronic lymphocytic leukemia (CLL) and other forms of Hodgkin and non-Hodgkin lymphoma, and he is passionate about working towards a cure for these malignancies. His research interests include the development and implementation of clinical trials, for which he is the principal investigator on multiple clinical trials at Huntsman Cancer Institute. He is also focused on outcomes research evaluating and improving on current standards of care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 35 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 28, 2024
    HUNTSMAN CANCER CENTER

    My doctor has been Deborah Stephens who recently left. I was so worried about her replacement. I¿m thrilled to be in the care of Dr. Ermann as my oncologist. I have a lot of trust in him. I just hope he stays with me.

    July 01, 2024
    HUNTSMAN CANCER CENTER

    A wonderful, caring doctor

    June 23, 2024
    HUNTSMAN CANCER CENTER

    Thanks again, Dr. Ermann. I look forward to our next visit, and becoming more educated regarding (CLL) [NAME REMOVED]

    May 20, 2024
    HUNTSMAN CANCER CENTER

    Excellent! He explains things well, is kind snd takes time to listen to me.

    May 17, 2024
    HUNTSMAN CANCER CENTER

    Dr. Ermann is the doctor I trust to take care of my CLL related issues. He is awesome.

    May 13, 2024
    HUNTSMAN CANCER CENTER

    Dr. Ermann has all the qualities of a knowledgeable and concerned physician for his patients.

    May 10, 2024
    HUNTSMAN CANCER CENTER

    He came in on time, was very attentive and addressed every concern.

    April 28, 2024
    HUNTSMAN CANCER CENTER

    Dr. Ermann is a very professional physician who is very detailed about your medical care and is a great listener.

    April 18, 2024
    HUNTSMAN CANCER CENTER

    If you have lymphoma, Dr Ermann is who you want taking care of you. Not only does he genuinely care and listen, but he's darn smart! He just caught a very rare occurrence in my blood that has saved me a lot of discomfort and possible heart damage. And he caught it very quickly. He never feels like he's rushing and is very attentive and includes me in the discussion. I can't say enough about Dr. Ermann. I trust him with my life and he and the BMT team basically saved my life.

    See More Patient Comments

  • Dr. Daniel Ermann joined the Division of Hematology/Hematologic malignancies in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. He specializes in the treatment of patients with chronic lymphocytic leukemia (CLL) and other forms of Hodgkin and non-Hodgkin lymphoma, and he is passionate about working towards a cure for these malignancies. His research interests include the development and implementation of clinical trials, for which he is the principal investigator on multiple clinical trials at Huntsman Cancer Institute. He is also focused on outcomes research evaluating and improving on current standards of care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Administrative Chief Fellow
    Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Fellow
    Residency Internal Medicine - Creighton University School of Medicine Chief Resident
    Internal Medicine - Creighton University School of Medicine Resident
    Professional Medical Medicine - St. George's University School of Medicine M.D.
    Major: Biology; Minor: Chemistry - University of Pittsburgh B.S.

    Selected Publications

    Journal Article

    1. Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M (2024). Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Blood Adv. (Read full article)
    2. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
    3. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. (Read full article)
    4. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. (Read full article)
    5. Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA (2022). Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem, 3(3), 930-935. (Read full article)
    6. Ermann DA, Vardell VA, Kallam A, Silberstein PT, Armitage JO (2019). Academic Centers Compared With Nonacademic Centers for Patients With International Prognostic Index Risk-stratified Diffuse Large B-cell Lymphoma: A Survival Outcomes Analysis. Clin Lymphoma Myeloma Leuk, 20(4), e174-e183. (Read full article)
    7. Pierce TP, Ermann D, Scillia AJ, Festa A, Emami A, McInerney VK (2019). National Trends in Orthopaedic Surgery Resident Adult Case Logs. J Surg Educ, 76(3), 893-897. (Read full article)
    8. Vardell Noble V, Ermann DA, Griffin EK, Silberstein PT (2019). Primary Thyroid Lymphoma: An Analysis of the National Cancer Database. Cureus, 11(2), e4088. (Read full article)
    9. Ermann DA, Noble VV, Fazeel HM, Thomas B, Silberstein PT (2019). Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. Fed Pract, 36(Suppl 1), S30-S33. (Read full article)

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. (Read full article)
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. (Read full article)

  • News & Podcasts

    Huntsman Cancer Institute News